Salveen Richter, an analyst from Goldman Sachs, maintained the Hold rating on Moderna. The associated price target was lowered to $34.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Salveen Richter has given his Hold rating due to a combination of factors affecting Moderna’s current position. The primary reason is the recent failure of Moderna’s Phase 3 study for its cytomegalovirus (CMV) vaccine, mRNA-1647, which did not achieve its primary efficacy endpoint. This setback has led to the discontinuation of clinical development in congenital disease, as the vaccine’s efficacy was significantly below the required threshold for regulatory approval.
Despite this, Moderna does not foresee an impact on its 2025 financial guidance or its breakeven expectations for 2028. Investors have shown caution regarding the commercial potential of the CMV vaccine, particularly concerning the target demographic and the necessary investments for market establishment. However, there is optimism in Moderna’s oncology pipeline, with upcoming data expected from its cancer antigen therapy and individualized neoantigen therapy, which could provide positive momentum for the company in the near future.
Richter covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Biogen, and Vertex Pharmaceuticals. According to TipRanks, Richter has an average return of 8.9% and a 45.40% success rate on recommended stocks.
In another report released yesterday, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $27.00 price target.